Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

NCT03690141 is registered in ClinicalTrials.gov with Effector Therapeutics as lead sponsor.

NCT NCT03690141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03690141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Lead sponsor
Effector Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 27, 2018
Completion date
April 27, 2020
Enrollment
16 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

castrate-resistant prostate cancer (crpc)